Navigation Links
Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
Date:8/19/2007

Estimates Peak Worldwide Transplant Opportunity of Over $400 Million

Annually

CAMBRIDGE, Mass., Aug. 2 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) today announced that its second phase 3 trial of Mozobil(TM) (plerixafor) has successfully met its primary and secondary endpoints, demonstrating positive results in multiple myeloma (MM) similar to those reported two weeks ago in non-Hodgkin's lymphoma.

The combined strength of these two trials -- in which patients with two types of cancer achieved more rapid and effective mobilization of stem cells in preparation for transplant than patients treated with current therapies -- will support Mozobil's regulatory approval, commercialization, and likely adoption as a standard of care in transplantation.

The randomized, double-blind, placebo-controlled trial included 302 patients who were undergoing a hematopoietic stem cell transplant (HSCT) for multiple myeloma at medical centers in the United States, Canada, and Europe. Like the previous trial, it examined the effectiveness of Mozobil in increasing the number of hematopoietic stem cells collected for a transplant, comparing the stem cell yield from patients treated with Mozobil following G- CSF to patients treated with placebo following G-CSF.

In the primary efficacy endpoint, 72 percent of patients treated with Mozobil and G-CSF achieved the target threshold for collection of at least 6 million CD34+cells/kg from the peripheral blood with two days or fewer of apheresis sessions, compared with 34 percent of patients in the G-CSF/placebo group. This two-fold increase was statistically significant in favor of the Mozobil-treated patients (p<0.0001). Like th
'/>"/>

SOURCE Genzyme Corp.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Sygnis Pharma AG announces date for presentation of clinical results
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015  Before you head outdoors with ... you can stay safe and healthy. Take steps to protect ... http://nyackhospital.org/summersafety Protect Your Skin From the ... sun can increase your risk of skin cancer. To protect ... much as possible, especially during midday hours. Wear a hat ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/n7kzjb/vitamin_d_market ) ... by Analog, Application, End-User & by Region - Global Trends ... This market is projected to reach about $2.5 Million ... applications and rising opportunities in countries such as ... Italy , and Brazil . In ...
(Date:7/2/2015)... 2, 2015 Numotion,s Board of Directors and ... Tamas Feitel has joined the Company as ... a highly successful 18 year career at GE serving ... profitability, and productivity to result in significant industry leading ... Chief Financial Officer for GE Healthcare Global Services, a ...
Breaking Medicine Technology:First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3Numotion Names Tamas Feitel Chief Financial Officer 2
... TAMPA, Fla.--(BUSINESS WIRE)--Mar 7, 2007 - Accentia,Biopharmaceuticals, Inc. ... of the American Academy of Allergy, Asthma, and,Immunology ... Diego, CA. The,posters discussed findings from a survey ... U.K., France, and Germany on the,burden of chronic ...
... trial data underlines M6G's,benefit compared to morphine ... England, 7th March 2007 - CeNeS Pharmaceuticals ... today,announces additional data from the pivotal Phase ... 500 patients with,post-operative pain. The preliminary data ...
Cached Medicine Technology:Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 2Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 3Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 5CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 2CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 3CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 4CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 5CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 6CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 7
(Date:7/3/2015)... ... 2015 , ... First Choice Emergency Room , the largest network of ... the new Medical Director of its Frisco facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:7/3/2015)... ... 2015 , ... Every year, One-to-1 Fitness and the Red Deer Fit ... Red Deer community with free fitness training and indoor fitness boot camp classes for ... entertainment raised thousands of charity dollars and ended with a $10,000 donation to the ...
(Date:7/2/2015)... ... ... pleased to announce the opening of its newest location in Dallas, Texas. The opening is ... chain was listed as #22 on the Inc. 500 list of fastest growing companies in ... located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We are excited ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... (D-Md.) for her introduction of the Stop Overdose Stat (S.O.S.) Act of 2015 ... Jack Reed (D-R.I.), this Act seeks to decrease drug overdose – especially of ...
(Date:7/2/2015)... ... July 02, 2015 , ... With summer in full swing, Americans are flocking to Canada’s many ... top spots for fishing in the world, and it’s easy to understand why. From the ... great fish. , Recreational fishing is a huge industry, and Americans make up the ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3
... By Serena Gordon HealthDay Reporter , TUESDAY, ... popular way to manage gluten sensitivity, but a new analysis ... need to do so. Health experts have claimed ... who are sensitive to gluten, a substance found in wheat, ...
... TUESDAY, Feb. 21 (HealthDay News) -- Raw, or unpasteurized, milk ... milk. And states where the sale of raw milk is ... is illegal, according to a new U.S. Centers for Disease ... between state laws and the number of outbreaks and illnesses ...
... recession was the longest and most severe since World War ... at the slowest rate in over 50 years, suggesting that ... that these cut backs were not limited to Americans who ... at the University of North Carolina at Chapel Hill School ...
... 21, 2012Babies are not able to metabolize or excrete ... caffeine may lead to caffeine accumulation and symptoms such ... expert Ruth Lawrence, MD, published in Journal of ... Liebert, Inc. The interview is available on the ...
... researchers have discovered more details about how an energy ... use their energy reserves. In a report in ... researchers showed that a chemical modification on the thermostat ... use stored energy, and with it, they default to ...
... , TUESDAY, Feb. 21 (HealthDay News) -- Giving flu ... a baby that is small for its gestational age, a new ... age have an increased risk of health problems and other issues ... Bangladesh who were divided into two groups -- 170 who received ...
Cached Medicine News:Health News:Is Avoiding Gluten in Foods Always Necessary? 2Health News:Is Avoiding Gluten in Foods Always Necessary? 3Health News:Raw Milk Causes Most Illness From Dairy Products: CDC 2Health News:Raw Milk Causes Most Illness From Dairy Products: CDC 3Health News:Recession and high co-pays tied to fewer colonoscopy screenings among people with health insurance 2Health News:Cell energy sensor mechanism discovered 2Health News:Flu Shots for Pregnant Moms May Protect Babies 2
CCR Medical conventional laryngoscope handles....
... ™ Airway., ,The LMA Flexible™ ... allows it to be positioned away ... a good seal. This makes it ... surgery, or other procedures where the ...
... an advancement in supralaryngeal airway management., ,The ... in the hypopharynx where it abuts the structure ... Cobra head design of the distal end of ... the epiglottis out of the way, facilitating ventilation ...
Robertazzi Latex Free Nasal Airways are manufactured from soft neoprene and have smooth beveled tip for gentle insertion....
Medicine Products: